Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer.
Authors
Li, ChenggangGuo, Baoqiang
Wilson, Philip B
Stewart, Alan L
Byrne, Ged J
Bundred, Nigel J
Kumar, Shant
Affiliation
Department of Pathological Sciences, Medical School, University of Manchester, UK.Issue Date
2000-03-20
Metadata
Show full item recordAbstract
CD105 (endoglin), a receptor for transforming growth factor (TGF) beta1 and beta3 in vascular endothelial cells, is highly up-regulated in blood vessels of tissues where neovascularisation occurs. It modulates endothelial-mesenchymal signalling and is essential for angiogenesis. Indeed, CD105 knock-out mice die from malvascularisation by 11.5 day p.c. In the present study CD105, TGFbeta1 and CD105/TGFbeta1 complexes were quantified in plasma samples from 77 healthy individuals and 92 patients with early stage breast cancer prior to any treatment. When compared with normal controls, both CD105 and CD105/TGFbeta1 complex levels were significantly elevated in breast cancer patients, whereas TGFbeta1 levels were lower in cancer patients. The most important finding to emerge was that CD105 levels were significantly increased in patients who developed distant metastasis compared with disease-free patients. While there was no significant difference between CD105 levels in controls compared to disease-free patients, it was significantly higher in patients with metastatic disease. Thus patients who had died following local relapse or distant metastases possessed the highest levels of CD105. Neither CD105/TGFbeta1 complex nor TGFbeta1 levels correlated with tumour progression. Our data indicate that CD105 might be a valuable novel angiogenic marker for identifying breast cancer patients who are at high risk of developing metastasis.Citation
Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. 2000, 89 (2):122-6 Int. J. CancerJournal
International Journal of CancerDOI
10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-MPubMed ID
10754488Type
ArticleLanguage
enISSN
0020-7136ae974a485f413a2113503eed53cd6c53
10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M
Scopus Count
Collections
Related articles
- Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer.
- Authors: Li C, Wang J, Wilson PB, Kumar P, Levine E, Hunter RD, Kumar S
- Issue date: 1998 Oct 23
- Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
- Authors: Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S
- Issue date: 2003 May 6
- TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis.
- Authors: Li C, Wilson PB, Levine E, Barber J, Stewart AL, Kumar S
- Issue date: 1999 Apr 20
- Immunodetection and characterisation of soluble CD105-TGFbeta complexes.
- Authors: Li CG, Wilson PB, Bernabeu C, Raab U, Wang JM, Kumar S
- Issue date: 1998 Sep 1
- The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease.
- Authors: Li CG, Bethell H, Wilson PB, Bhatnagar D, Walker MG, Kumar S
- Issue date: 2000 Sep